Doubling Survival in Pancreatic Cancer, Rethinking Obesity, and The Return of Maggot Therapy

This week, Dr. Joe looks at how new science is reshaping everything from one of the deadliest cancers to how we talk about weight—and even what we’re willing to use to heal a wound. A phase III trial of a new oral pill for metastatic pancreatic cancer has been called a “grand slam,” with patients on the drug living about 13 months on average compared with 6 months on standard chemotherapy. Dr. Joe explains how targeting a common RAS gene pathway can double survival while preserving quality of life, and why genetic markers are becoming as important as where a cancer starts. An international commission of 56 experts, backed by 76 medical organizations, says it is time to stop treating all obesity the same and instead distinguish between “clinical” obesity that harms organs and “preclinical” obesity where weight has not yet caused damage. Dr. Joe breaks down how labeling weight as a disease versus a risk factor changes insurance coverage, treatment options, and the key question patients should ask: “Is my weight actually affecting my health?” Maggot therapy is quietly making a comeback, with FDA‑cleared, lab‑raised larvae used to dissolve dead tissue while sparing healthy skin in hard‑to‑treat wounds. Dr. Joe talks about why this biologic “scalpel” can help people who cannot undergo surgery, the science behind its precision, and how medicine sometimes leans on nature—even when the “yuck factor” is high. See omnystudio.com/listener for privacy information.